Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Improved Biomarkers and Clinical Outcome Measures, 2016
    Supramolecular Hosts as Combined Protein Aggregation Inhibitors and Hyperpolarized MRI Reporters

    Study Rationale:
    Amyloid fibrils play a key role in Parkinson's disease (PD) and monitoring of their formation from self‐assembled insoluble molecular aggregates would be extremely valuable as a...

  • Access to Data and Biospecimens, 2016
    Evaluation of Glucocerebrosidase Pathway Biomarkers in Parkinson's Disease

    Study Rationale: 

    Parkinson disease (PD) due to monoallelic glucocerebrosidase (GBA1) gene mutations (GBA-PD) is at the forefront of novel approaches to the treatment of PD. Exciting potential...

  • Research Grant, 2016
    Identification of Epigenetic Signatures in Blood as Biomarkers for Parkinson's Disease

    Study Rationale:
    Epigenetic processes (changes in gene expression), such as DNA methylation (mechanism that cells use to control gene expression), ensure proper functioning of genetic materials in...

  • Biomarker Development, 2015
    Development of Novel, Small Molecule Compounds as PET Tracers for Synucleinopathies

    Study Rationale:
    Our project aims to develop a brain imaging agent for alpha-synuclein, a key protein involved in Parkinson’s disease (PD) pathology. Such an agent will help (i) diagnose PD earlier,...

  • Access to Data and Biospecimens, 2015
    Lysosomal Enzyme Activity and GBA1 Genotyping in Parkinson’s Disease

    Study Rationale:                   
    The dysfunction of the systems responsible for the clearance of the protein alpha-synuclein plays a major role in Parkinson’s disease (PD). The lysosome is an...

  • Therapeutic Pipeline Program, 2015
    Utilization of Aptamers to Prevent Protein Aggregation in Parkinson’s Disease

    Objective/Rationale:             
    The abnormal aggregation of a protein known as alpha-synuclein appears to play a critical role in Parkinson's disease. This project will explore a new type of...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.